Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
ADC Therapeutics, a Swiss developer of antibody-drug conjugates for cancer, has raised $105 million from new and existing investors including AstraZeneca, Auven Therapeutics, and the Wild Family Office. ADC’s drugs use antibodies to deliver pyrrolobenzodiazepine-based warheads to both solid tumors and hematological malignancies. ADC says it has raised $255 million since its inception in 2012. Two of its drugs, ADCT-301 and ADCT-402, are in clinical studies against lymphoma and leukemia. Its next two drug candidates will target solid tumors.
This article has been sent to the following recipient: